Ownership and insider activity for BeOne Medicines AG (ONC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult...
Price
| Price | $377.63 (closing price, October 28, 2026) |
| Market Cap | $40.4B |
| Exchange | NASDAQ |
| Country | CH |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-13 | Wang Xiaodong | M-Exempt | 403,351 | $1.1M |
| 2026-10-13 | Wang Xiaodong | M-Exempt | 31,027 | $1.1M |
| 2026-10-13 | Wang Xiaodong | S-Sale | 7,167 | $2.5M |
| 2026-10-13 | Wang Xiaodong | S-Sale | 10,361 | $3.6M |
| 2026-10-13 | Wang Xiaodong | S-Sale | 5,681 | $2.0M |
| 2026-10-13 | Wang Xiaodong | S-Sale | 6,558 | $2.3M |
| 2026-10-13 | Wang Xiaodong | S-Sale | 1,260 | $445K |
| 2026-09-30 | Lee Chan Henry | S-Sale | 1,115 | $418K |
| 2026-09-28 | Wang Xiaodong | M-Exempt | 403,364 | $1.1M |
| 2026-09-28 | Wang Xiaodong | M-Exempt | 31,028 | $1.1M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $87.5M | $239.6M | $712.9M | $618.0M | $1.38B | $4.38B | $3.87B | $3.17B | $2.63B | $4.55B |
| Short-term Investments | $280.7M | $597.9M | $1.07B | $364.7M | $3.27B | $2.24B | $665.3M | $2.6M | 0 | 0 |
| Receivables | 0 | $29.4M | $49.7M | $70.9M | $60.4M | $500.2M | $199.0M | $395.9M | $709.1M | $886.9M |
| Inventory | 0 | $10.9M | $16.2M | $28.6M | $89.3M | $242.6M | $282.3M | $416.1M | $495.0M | $608.2M |
| Total Current Assets | $374.4M | $913.5M | $1.94B | $1.17B | $4.96B | $7.61B | $5.21B | $4.20B | $3.99B | $6.23B |
| Property, Plant & Equipment | $26.0M | $62.6M | $194.2M | $324.9M | $446.3M | $662.5M | $924.0M | $1.37B | $1.66B | $1.79B |
| Goodwill | 0 | $109,000 | $109,000 | $109,000 | $109,000 | $109,000 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $19.7M | $52.2M | $5.8M | $53.7M | $103.3M | $94.6M | $108.9M | $129.8M | $62.7M |
| Total Assets | $405.8M | $1.05B | $2.25B | $1.61B | $5.60B | $8.54B | $6.38B | $5.81B | $5.92B | $8.19B |
| Accounts Payable | $12.0M | $69.8M | $113.3M | $122.5M | $232.0M | $262.4M | $294.8M | $315.1M | $405.0M | $479.0M |
| Short-term Debt | 0 | $9.2M | $8.7M | 0 | $335.0M | $427.6M | $329.0M | $688.4M | $851.5M | $134.7M |
| Total Current Liabilities | $35.1M | $150.0M | $246.5M | $310.3M | $1.08B | $1.60B | $1.47B | $1.81B | $2.21B | $1.83B |
| Long-term Debt | $17.3M | $155.5M | $189.7M | $240.7M | $183.6M | $202.1M | $209.1M | $197.6M | $166.5M | $1.81B |
| Total Liabilities | $52.9M | $362.2M | $496.0M | $633.9M | $1.73B | $2.40B | $2.00B | $2.27B | $2.59B | $3.83B |
| Retained Earnings | -$237.4M | -$330.5M | -$1.01B | -$1.96B | -$3.55B | -$5.08B | -$7.08B | -$7.96B | -$8.61B | -$8.32B |
| Total Equity | $352.9M | $684.2M | $1.75B | $962.2M | $3.87B | $6.13B | $4.38B | $3.54B | $3.33B | $4.36B |
| Total Debt | $17.3M | $164.7M | $198.4M | $277.3M | $562.0M | $694.6M | $596.7M | $930.2M | $1.08B | $2.00B |
| Net Debt | -$350.9M | -$672.8M | -$1.58B | -$705.4M | -$4.09B | -$5.92B | -$3.94B | -$2.24B | -$1.55B | -$2.55B |
| Working Capital | $339.3M | $763.5M | $1.70B | $862.4M | $3.89B | $6.01B | $3.74B | $2.39B | $1.78B | $4.40B |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 3.40 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 5.25 |
Profitability
| Return on Equity | 14.27% |
| Return on Invested Capital | 9.63% |
| Return on Assets | 7.17% |
| Gross Margin | 87.82% |
| Operating Margin | 15.05% |
| Net Margin | 10.68% |
Related companies: VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ONC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks